AR057823A1 - Compuestos quimicos derivados de quinazolina, un metodo para su preparacion y composicion farmaceutica - Google Patents

Compuestos quimicos derivados de quinazolina, un metodo para su preparacion y composicion farmaceutica

Info

Publication number
AR057823A1
AR057823A1 ARP060104116A ARP060104116A AR057823A1 AR 057823 A1 AR057823 A1 AR 057823A1 AR P060104116 A ARP060104116 A AR P060104116A AR P060104116 A ARP060104116 A AR P060104116A AR 057823 A1 AR057823 A1 AR 057823A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
hydrogen
optionally contains
independently selected
Prior art date
Application number
ARP060104116A
Other languages
English (en)
Inventor
Robert Hugh Bradbury
Richard Ducray
Bernard Christophe Barlaam
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR057823A1 publication Critical patent/AR057823A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Existe un efecto anti-proliferativo, que se produce total o parcialmente a través de la inhibicion de la tirosina quinasa de receptores erbB2, en un animal de sangre caliente, tal que el hombre. Estos compuestos son utiles en la prevencion o tratamiento de las enfermedades de tumores solidos en animales caliente. Proceso de preparacion de los compuestos y composicion farmacéutica en base a aquellos. Reivindicacion 1: Un derivado de quinazolina caracterizado porque responde a la formula (1), donde: R1 se selecciona entre hidrogeno, hidroxi, alcoxi C1-4 y alcoxi C1-4-alcoxi C1-4; G1, G2, G3 y G4 se seleccionan cada uno independientemente entre hidrogeno y halogeno; X1 se selecciona entre SO2, CO, SO2N(R6) y C(R6)2, donde cada R6 se selecciona independientemente entre hidrogeno y alquilo C1-4; Q1 es arilo o heteroarilo, donde dicho grupo arilo o heteroarilo contiene optativamente uno o más sustituyentes seleccionados independientemente entre halogeno, ciano, alcoxi C1-4 y alquilo C1-4; R2 y R3, que pueden ser iguales o diferentes, se seleccionan entre hidrogeno, alquenilo C2-4, alquinilo C2-4 y alquilo C1-4, el cual alquilo C1-4 contiene optativamente uno o más sustituyentes hidroxi, o R2 y R3 junto con el átomo de carbono al cual están unidos forman un anillo ciclopropilo; R4 y R5, que pueden ser iguales o diferentes, se seleccionan entre hidrogeno, alquenilo C3-4, alquinilo C3-4 y alquilo C1-4, el cual alquilo C1-4 contiene optativamente uno o más sustituyentes seleccionados independientemente entre halogeno, ciano, hidroxi, amino, alquilamino C1-4, di-(alquilo C1-4)amino y alcoxi C1-4; o R4 y R5 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico de 4, 5, 6 o 7 miembros que contiene optativamente uno o más heteroátomos seleccionados independientemente entre oxígeno, S, SO, SO2 y N(R7), donde R7 se selecciona entre hidrogeno y alquilo C1-4, y donde cualquier anillo heterocíclico formado por R4, R5 y el átomo de nitrogeno al cual están unidos contiene optativamente uno o más sustituyentes seleccionados independientemente entre halogeno, ciano, hidroxi, alquilo C1-4 y alcoxi C1-4; y donde cualquier anillo heterocíclico formado por R4, R5 y el átomo de nitrogeno al cual están unidos contiene optativamente 1 o 2 sustituyentes oxo o tioxo; o una sal aceptable para uso farmacéutico de los mismos.
ARP060104116A 2005-09-20 2006-09-20 Compuestos quimicos derivados de quinazolina, un metodo para su preparacion y composicion farmaceutica AR057823A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05291948 2005-09-20
EP05292547 2005-12-02
EP06300343 2006-04-07

Publications (1)

Publication Number Publication Date
AR057823A1 true AR057823A1 (es) 2007-12-19

Family

ID=37434116

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104116A AR057823A1 (es) 2005-09-20 2006-09-20 Compuestos quimicos derivados de quinazolina, un metodo para su preparacion y composicion farmaceutica

Country Status (11)

Country Link
US (1) US7820683B2 (es)
EP (1) EP1928861B1 (es)
JP (1) JP2009508918A (es)
AR (1) AR057823A1 (es)
AT (1) ATE488513T1 (es)
DE (1) DE602006018331D1 (es)
ES (1) ES2354457T3 (es)
HK (1) HK1120793A1 (es)
TW (1) TW200745090A (es)
UY (1) UY29801A1 (es)
WO (1) WO2007034144A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441492C (en) * 2001-03-23 2011-08-09 Bayer Corporation Rho-kinase inhibitors
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
JP4881875B2 (ja) * 2004-12-14 2012-02-22 アストラゼネカ アクチボラグ 抗腫瘍剤としてのピラゾロピリミジン化合物
CA2755095A1 (en) * 2009-03-09 2010-09-16 Surface Logix, Inc. Rho kinase inhibitors
TWI811358B (zh) * 2018-05-08 2023-08-11 大陸商迪哲（江蘇）醫藥股份有限公司 ＥｒｂＢ受體抑制劑
WO2024085661A1 (en) * 2022-10-18 2024-04-25 Ildong Pharmaceutical Co., Ltd. Novel triheterocyclic compounds

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
GB2160201B (en) 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
KR910006138B1 (ko) 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US4921863A (en) 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
JPH083144A (ja) 1994-06-21 1996-01-09 Chugai Pharmaceut Co Ltd キナゾリン及びキノリン誘導体
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (es) 1994-11-12 1997-12-01 Zeneca Ltd
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996033977A1 (en) 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
GB9508535D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
EP0850055B1 (en) 1995-09-11 2005-06-29 Osteoarthritis Sciences, Inc. Protein tyrosine kinase inhibitors for treating osteoarthritis
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ES2237789T3 (es) 1996-01-31 2005-08-01 Cosmoferm B.V. Utilizacion de composiciones que comprenden enzimas estabilizantes.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
CA2249446C (en) 1996-04-12 2008-06-17 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
BR9710362A (pt) 1996-07-13 1999-08-17 Glaxo Group Ltd Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
AU3766897A (en) 1996-07-13 1998-02-09 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6004967A (en) 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
ES2384551T3 (es) 1997-03-05 2012-07-06 Sugen, Inc. Formulaciones para agentes farmacéuticos hidrófobos
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
JP4327259B2 (ja) 1997-05-06 2009-09-09 ワイス・ホールディングズ・コーポレイション 多発性嚢胞腎の治療のためのキナゾリン化合物の使用
US5929080A (en) 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
NZ503991A (en) 1997-11-06 2001-11-30 American Cyanamid Co Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
JP4245682B2 (ja) 1997-12-25 2009-03-25 協和発酵キリン株式会社 キノリン誘導体、イソキノリン誘導体、およびシンノリン誘導体、並びに抗炎症剤および抗アレルギー剤
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
MXPA00011773A (es) 1998-05-28 2002-06-04 Parker Hughes Inst Quinazolinas para tratar tumores en el cerebro.
WO2000000202A1 (en) 1998-06-30 2000-01-06 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
BR9912575A (pt) 1998-07-30 2001-05-02 American Home Prod Processo para a preparação de um composto, e, composto.
US6384223B1 (en) 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
AU5195999A (en) 1998-08-11 2000-03-06 Takeda Chemical Industries Ltd. Cyclic amide compounds, process for producing the same, intermediates thereof and herbicides
DE69924500T2 (de) 1998-08-21 2006-02-09 Parker Hughes Institute, St. Paul Chinazolinderivate
AU6159499A (en) 1998-09-29 2000-04-17 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
ES2191462T3 (es) 1998-10-01 2003-09-01 Astrazeneca Ab Derivados de quinolina y quinazolina y su uso como inhibidores de enfermedades mediadas por citoquinas.
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
AU3281600A (en) 1999-02-27 2000-09-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US20020082270A1 (en) 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
WO2002066445A1 (fr) 2001-02-21 2002-08-29 Mitsubishi Pharma Corporation Derives de la quinazoline
US6562319B2 (en) 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
WO2003040108A1 (en) 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
CN1642552B (zh) 2002-03-30 2010-05-12 贝林格尔英格海姆法玛两合公司 作为酪氨酸激酶抑制剂的4-(n-苯氨基)-喹唑啉/喹啉
GB0309009D0 (en) 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
WO2005012290A1 (en) 2003-07-29 2005-02-10 Astrazeneca Ab Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
CA2538884C (en) 2003-09-16 2010-09-21 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
KR20070027487A (ko) 2003-09-16 2007-03-09 아스트라제네카 아베 퀴나졸린 유도체
JP2007505873A (ja) 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ チロシンキナーゼ阻害剤としてのキナゾリン誘導体
JP2007505878A (ja) 2003-09-19 2007-03-15 アストラゼネカ アクチボラグ キナゾリン誘導体
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
BRPI0414735A (pt) 2003-09-25 2006-11-21 Astrazeneca Ab derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina
DE10350717A1 (de) 2003-10-30 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
WO2005075439A1 (en) 2004-02-03 2005-08-18 Astrazeneca Ab Quinazoline derivatives
US20070232607A1 (en) 2004-06-04 2007-10-04 Bradbury Robert H Quinazoline Derivatives as Erbb Receptor Tyrosine kinases
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
ES2354457T3 (es) 2011-03-15
ATE488513T1 (de) 2010-12-15
WO2007034144A1 (en) 2007-03-29
DE602006018331D1 (de) 2010-12-30
UY29801A1 (es) 2007-04-30
EP1928861B1 (en) 2010-11-17
US20090048251A1 (en) 2009-02-19
TW200745090A (en) 2007-12-16
HK1120793A1 (en) 2009-04-09
EP1928861A1 (en) 2008-06-11
JP2009508918A (ja) 2009-03-05
US7820683B2 (en) 2010-10-26

Similar Documents

Publication Publication Date Title
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
CO6220949A2 (es) Derivados pirazolicos como inhibidores de la 11 beta -hsd1
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
PE20050664A1 (es) Derivados de 1h-imidazo[4,5-c]quinolina
AR071609A1 (es) Inhibidores ciclicos de 11(beta) -hidroxiesteroide deshidrogenasa 1
PE20080841A1 (es) Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
AR060050A1 (es) Compuestos moduladores del receptor de s1p y uso de los mismos
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
AR054799A1 (es) Derivados de oxindol
AR048669A1 (es) Derivados biciclicos de bisamida
AR057823A1 (es) Compuestos quimicos derivados de quinazolina, un metodo para su preparacion y composicion farmaceutica
AR055074A1 (es) Derivados de heteroaril benzamidas como activadores de glk en el tratamiento de diabetes. procesos de obtencion y composiciones farmaceuticas.
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20050951A1 (es) Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas
PE20090900A1 (es) Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol como inhibidores del receptor del factor de creciemiento de hepatocitos (met), su procedimiento de preparacion y una composicion farmaceutica que los contiene
PE20060664A1 (es) Amidas biciclicas como inhibidores de cinasa
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20080139A1 (es) Compuestos de pirrolotriazina anilina como inhibidores de cinasa
AR049883A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
ATE556712T1 (de) A2a antagonisten zur behandlung von motorischen störungen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal